Abstract
BACKGROUND: Historically, the first treatment choices for hairy cell leukemia (HCL) were splenectomy and alphainterferon. Recently, purine analogues (pentostatin and cladribine) changed radically the treatment modality, inducing complete and durable responses in the majority of patients. METHODS: The authors analyzed the outcome of different lines of therapy in 121 HCL patients followed in their institute from 1986 to 2008, with a median follow-up of 105 months. Patients were divided into subgroups according to the number of treatments; Group A included 121 patients who underwent a front-line therapy, Group B patients (n = 53) were treated with 2 lines, Group C patients (n = 34) with 3 lines, Group D patients (n = 17) with 4 lines, and Group E patients (n = 8) with 5 lines. RESULTS: In Group A, 92 (77%) patients obtained a complete response (CR), 23 (18%) a partial response, and the remaining 6 (5%) a minor or no response; median duration of response was 2.7 years. In Group B, 53 relapsed patients achieved a second CR rate of 73.5%; median duration of response was 2.5 years. Group C contained 34 patients in a second relapse, with a CR rate after the third line of treatment of 70.5% (median duration of response, 2.2 years). In Group D, 11 (64.7%) patients obtained a CR (median duration of response, 1.6 years), and in Group E 4 (50%) of 8 patients achieved a CR (median duration of response, 1.3 years). CONCLUSIONS: This study confirms the high risk (>40% of all patients) of retreatment of HCL patients and the need to maximize primary response.
| Original language | English |
|---|---|
| Pages (from-to) | 4788-4792 |
| Number of pages | 5 |
| Journal | Cancer |
| Volume | 116 |
| Issue number | 20 |
| DOIs | |
| Publication status | Published - 2010 |
Fingerprint
Keywords
- Alpha-interferon
- Cladribine
- Hairy cell leukemia
- Pentostatin
- Rituximab
- Splenectomy
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Hairy cell leukemia : Evaluation of the long-term outcome in 121 patients. / Zinzani, Pier Luigi; Pellegrini, Cinzia; Stefoni, Vittorio; Derenzini, Enrico; Gandolfi, Letizia; Broccoli, Alessandro; Argnani, Lisa; Quirini, Federica; Pileri, Stefano; Baccarani, Michele.
In: Cancer, Vol. 116, No. 20, 2010, p. 4788-4792.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hairy cell leukemia
T2 - Evaluation of the long-term outcome in 121 patients
AU - Zinzani, Pier Luigi
AU - Pellegrini, Cinzia
AU - Stefoni, Vittorio
AU - Derenzini, Enrico
AU - Gandolfi, Letizia
AU - Broccoli, Alessandro
AU - Argnani, Lisa
AU - Quirini, Federica
AU - Pileri, Stefano
AU - Baccarani, Michele
PY - 2010
Y1 - 2010
N2 - BACKGROUND: Historically, the first treatment choices for hairy cell leukemia (HCL) were splenectomy and alphainterferon. Recently, purine analogues (pentostatin and cladribine) changed radically the treatment modality, inducing complete and durable responses in the majority of patients. METHODS: The authors analyzed the outcome of different lines of therapy in 121 HCL patients followed in their institute from 1986 to 2008, with a median follow-up of 105 months. Patients were divided into subgroups according to the number of treatments; Group A included 121 patients who underwent a front-line therapy, Group B patients (n = 53) were treated with 2 lines, Group C patients (n = 34) with 3 lines, Group D patients (n = 17) with 4 lines, and Group E patients (n = 8) with 5 lines. RESULTS: In Group A, 92 (77%) patients obtained a complete response (CR), 23 (18%) a partial response, and the remaining 6 (5%) a minor or no response; median duration of response was 2.7 years. In Group B, 53 relapsed patients achieved a second CR rate of 73.5%; median duration of response was 2.5 years. Group C contained 34 patients in a second relapse, with a CR rate after the third line of treatment of 70.5% (median duration of response, 2.2 years). In Group D, 11 (64.7%) patients obtained a CR (median duration of response, 1.6 years), and in Group E 4 (50%) of 8 patients achieved a CR (median duration of response, 1.3 years). CONCLUSIONS: This study confirms the high risk (>40% of all patients) of retreatment of HCL patients and the need to maximize primary response.
AB - BACKGROUND: Historically, the first treatment choices for hairy cell leukemia (HCL) were splenectomy and alphainterferon. Recently, purine analogues (pentostatin and cladribine) changed radically the treatment modality, inducing complete and durable responses in the majority of patients. METHODS: The authors analyzed the outcome of different lines of therapy in 121 HCL patients followed in their institute from 1986 to 2008, with a median follow-up of 105 months. Patients were divided into subgroups according to the number of treatments; Group A included 121 patients who underwent a front-line therapy, Group B patients (n = 53) were treated with 2 lines, Group C patients (n = 34) with 3 lines, Group D patients (n = 17) with 4 lines, and Group E patients (n = 8) with 5 lines. RESULTS: In Group A, 92 (77%) patients obtained a complete response (CR), 23 (18%) a partial response, and the remaining 6 (5%) a minor or no response; median duration of response was 2.7 years. In Group B, 53 relapsed patients achieved a second CR rate of 73.5%; median duration of response was 2.5 years. Group C contained 34 patients in a second relapse, with a CR rate after the third line of treatment of 70.5% (median duration of response, 2.2 years). In Group D, 11 (64.7%) patients obtained a CR (median duration of response, 1.6 years), and in Group E 4 (50%) of 8 patients achieved a CR (median duration of response, 1.3 years). CONCLUSIONS: This study confirms the high risk (>40% of all patients) of retreatment of HCL patients and the need to maximize primary response.
KW - Alpha-interferon
KW - Cladribine
KW - Hairy cell leukemia
KW - Pentostatin
KW - Rituximab
KW - Splenectomy
UR - http://www.scopus.com/inward/record.url?scp=78349281132&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78349281132&partnerID=8YFLogxK
U2 - 10.1002/cncr.25243
DO - 10.1002/cncr.25243
M3 - Article
C2 - 20597132
AN - SCOPUS:78349281132
VL - 116
SP - 4788
EP - 4792
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 20
ER -